关于我们
Eligo Bioscience was founded in 2014 as a spin-off from MIT and the Rockefeller University based on the discoveries from the Lu and Marraffini labs. The company develops a new generation of biotherapeutics that enable the expression of genetic circuits within target microbial populations and treat a wide-range of bacteria-associated unmet medical needs both in humans and animals. The company has won several international awards, has raised a US$3M seed-round in July 2015 and is currently located at Institut Pasteur in the heart of Paris.